Abstract
Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have